Find A Clinical Trial

Disease Type: Solid Tumors All

Trial ID TOS-358-001
Sponsor ID Totus

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

Trial ID NP-G2-044-P2-01
Sponsor ID Novita

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Trial ID KB-0742-1001
Sponsor ID Kronos Bio

“Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma”

Trial ID GO41596
Sponsor ID Genentech

“A PHASE Ia/Ib, OPEN-LABEL, MULTICENTER, GLOBAL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF XmAb24306 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS”

Trial ID BT5528-100
Sponsor ID REFMAL 631

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression

Trial ID BGB-A317-15025-101
Sponsor ID BeiGene

A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in Subjects with Advanced Solid Tumors

Trial ID ARC-12
Sponsor ID Arcus Biosciences

“A PHASE 1/1B STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AB308 IN COMBINATION WITH AB122 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES”

Trial ID 22003
Sponsor ID SPK101JG

“A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)”

Trial ID 21552
Sponsor ID RGX-104-001

“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”

Trial ID 21377
Sponsor ID 20190135-Subprotocol N

“20190135: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N) “